RSS | Login | Register

ZYLOPRIM

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare ZYLOPRIM to:

Generic Name for ZYLOPRIM

Allopurinol 100mg, 300mg; scored tabs.

Legal Classification:

Pharmacological Class for ZYLOPRIM

Xanthine oxidase inhibitor.

Manufacturer of ZYLOPRIM

Prometheus Labs, Inc.

Indications for ZYLOPRIM

Gout.

Adult dose for ZYLOPRIM

Take with food. Initially 100mg daily. Maintain prophylactic therapy initially. Increase by 100mg daily increments at weekly intervals; max 800mg/day and 300mg/dose. Usual range: mild: 200–300mg daily; severe: 400–600mg daily.

Children's dosing for ZYLOPRIM

Not recommended.

Warnings/Precautions for ZYLOPRIM

Discontinue if rash occurs. Renal or hepatic dysfunction. Monitor blood, renal, and hepatic tests for first few months of therapy. Maintain neutral or alkaline urine and increase urine output to ≥2 liters daily. Pregnancy (Cat.C). Nursing mothers.

Interactions for ZYLOPRIM

Increase in azathioprine and mercaptopurine toxicity. May potentiate oral anticoagulants, chlorpropamide, cyclosporine. Uricosurics reduce drug effect. Increased rash with ampicillin, amoxicillin. Monitor renal function with thiazides.

Adverse Reactions for ZYLOPRIM

Rash, GI disorders, acute gout, ecchymosis, fever, headache, hepatic necrosis, drowsiness, neuritis, arthralgia, necrotizing angiitis, blood dyscrasias, bone marrow depression, toxic skin reactions (eg, Stevens-Johnson syndrome), renal failure.

How is ZYLOPRIM supplied?

100mg—100
300mg—100, 500

Related Disease:

Gout

Hyperuricemia

Phase 3 trial of Arcalyst for prevention of gout flares

June 09, 2010

Regeneron announced that its Phase 3 study of Arcalyst (rilonacept injection) met its primary and secondary endpoints for the prevention of gout attacks.

Phase 2 study of BCX4208 for gout

June 01, 2010

BioCryst Pharmaceuticals announced it is initiating a Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

New Colcrys dosing when administered with protease inhibitors

May 07, 2010

URL Pharma, Inc., today announced that the FDA has issued new label information affecting all approved protease inhibitors for treatment of HIV when co-administered with Colcrys (colchicine).

Resubmitted BLA accepted by FDA for Krystexxa for treatment of chronic gout

March 30, 2010

Savient Pharmaceuticals, Inc. announced that the FDA has acknowledged receipt of and accepted for review the resubmission of the Biologics License Application (BLA) for Krystexxa (pegloticase), a treatment for chronic gout in patients refractory to conventional therapy.